The newly-formed Risk, Detection and Outcomes (RDO) Program has 49 members (47 primary, 2 associate) from 19 departments and is led by Drs. Paul Scheet (human genetics, computational biology) with co-leaders Sanjay Shete (biostatistics, genetic epidemiology, population health), Samir Hanash (early detection, proteomics), and Sharon Giordano (health care delivery, outcomes). The major scientific goal of the RDO Program is to reduce the cancer burden in the population and improve quality of life in survivors through innovative research aimed at optimizing cancer risk assessment, screening, early detection, and treatment- associated outcomes from diagnosis through survivorship, with an ultimate goal of informing successful interventions (e.g., in the Cancer Prevention Program). To achieve this goal, the RDO Program is organized into 3 specific aims focusing on 1) Cancer Etiology, 2) Early Detection, and 3) Care Delivery and Outcomes.
Aim 1 : To discover genetic, behavioral, and environmental factors for cancer initiation.
Aim 2 : To perform biomarker discovery for personalized risk assessment and early detection.
Aim 3 : To identify biological and social factors influencing care delivery and patient outcomes. The annual direct peer-reviewed funding of the RDO Program totals $11.4M, including 4 U01s, of which $5.4M (47%) is from the NCI. Over the past 6 years, program members have authored 1211 published peer-reviewed papers, with 373 (31%) intra-programmatic, 594 (49%) inter- programmatic, and 877 (72%) external collaborations. Forty-five percent of articles appeared in journals with IF >5, and 14% appeared in journals with IF >10, including Nat Biotechnol, Nat Genet and J Clin Oncol. Program members used all 14 shared resources. Over this period, the RDO Program has had several major accomplishments. First, in whole-genome genetic epidemiology studies, we identified genetic variants that predispose to disease initiation, affect outcomes, or predict adverse responses to therapy. In multiple whole- exome next-generation sequencing studies, the first of their kind, we are powered to discover variants of higher, intermediate cancer risk. We have also surveyed genomic changes in precancerous tissues, shedding light on early disease pathology. Second, we have uncovered novel blood-based biomarkers for early detection through state-of-the-art profiling technologies. Key hits identified from proteomics and metabolomics promise to complement low-dose CT scans in individuals at high risk for lung cancer. Third, as leaders in a consortium of Texas academic institutions and the Texas Cancer Registry, we have studied patterns of screening, diagnosis, treatment (e.g., chemotherapy and associated decision-making), and follow-up to impact state-wide policy. For all of these endeavors, we continue to develop and enhance unique cohorts, including Cancer Patients and Survivors, Mexican American, Premalignant Genome Atlas, Childhood Cancer Survivors, and organ-specific cohorts of the lung, breast, and ovary.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-44
Application #
9997833
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Sankhala, Kamalesh; Takimoto, Chris H; Mita, Alain C et al. (2018) Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Invest New Drugs :
Shen, Weining; Ning, Jing; Yuan, Ying et al. (2018) Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics 74:239-248
Wu, Shaofang; Wang, Shuzhen; Gao, Feng et al. (2018) Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma. Neuro Oncol 20:78-91
Romano, Gabriele; Chen, Pei-Ling; Song, Ping et al. (2018) A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov 8:556-567
Dray, Beth K; Raveendran, Muthuswamy; Harris, R Alan et al. (2018) Mismatch repair gene mutations lead to lynch syndrome colorectal cancer in rhesus macaques. Genes Cancer 9:142-152
Keene, Kimberly S; King, Tari; Hwang, E Shelley et al. (2018) Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer 4:34
Zhang, Miao; Adeniran, Adebowale J; Vikram, Raghunandan et al. (2018) Carcinoma of the urethra. Hum Pathol 72:35-44
Ciurea, Stefan O; Bittencourt, Maria Cecilia Borges; Milton, DenĂ¡i R et al. (2018) Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Adv 2:2254-2261
Chiu, Hua-Sheng; Somvanshi, Sonal; Patel, Ektaben et al. (2018) Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Rep 23:297-312.e12
Zhang, Yu; Zoltan, Michelle; Riquelme, Erick et al. (2018) Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. Gastroenterology 155:210-223.e3

Showing the most recent 10 out of 12418 publications